α-chlorovinyl phenyl sulfone | 119197-76-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: α-chlorovinyl phenyl sulfone
• 英文别名: 1-Chloroethenylsulfonylbenzene
• CAS: 119197-76-1
• 化学式: C₈H₇ClO₂S
• 分子量: 202.661
• InChiKey: HVEFQANHNATQJP-UHFFFAOYSA-N

物化性质

• 沸点：
  88-89 °C(Press: 0.05 Torr)
• 密度：
  1.315±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  甲胺 、 α-chlorovinyl phenyl sulfone 以 乙醇 为溶剂， 以94%的产率得到N-methyl-β-chloro-β-phenylsulfonylethyl amine
  参考文献：
  名称：

  bN-氯乙氨基碳负离子的分子内反应合成取代的氮丙啶

  摘要：

  通过在1-N-氯-2-烷氧基羰基（氰基、苯磺酰基）乙胺中进行氯化物的分子内亲核取代，阐述了一种简单、有效的合成2-烷氧基羰基、2-氰基、2-苯磺酰基N-烷基氮丙啶的方法。这些取代的 N-氯胺很容易通过伯胺加合物与迈克尔受体的 N-氯化作用而擦除。

  DOI：

  10.3987/com-08-s(n)115
• 作为产物：
  描述：

  氯甲基苯硫醚 在 N-氯代丁二酰亚胺 、 间氯过氧苯甲酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 、 氯苯 为溶剂， 生成 α-chlorovinyl phenyl sulfone
  参考文献：
  名称：

  Stereoselective Horner-Wittig synthesis of (Z)-1-chlorovinyl sulfoxides

  摘要：

  This paper describes the synthesis of (Z)-I-chlorovinyl sulfoxides 1 by the Horner-Wittig reaction. The required [(alpha-chloro)sulfinylmethyl]diphenylphosphine oxides 2 (R-1=Me, c-Hex, Ph, p-Tol, p-(CF3)Ph), were prepared in high yields by selective monochlorination and subsequent mono-oxidation of (thiomethyl)diphenylphosphine oxides 3. The stable lithiated anions of 2 gave an efficient reaction with all structural types of aldehydes. Aromatic and alpha,beta-unsaturated aldehydes gave 1 with excellent Z-selectivity (>98%), irrespective of the nature of the substituent R-1 at sulfur. With straight chain aliphatic aldehydes, an aromatic substituent at sulfur was required to obtain high Z-selectivity. A mechanistic explanation for these observations is presented. An X-ray analysis of 1, R-1=Me, R-2=4-MeOC6H4 confirmed the Z-disposition of the chloro and aryl substituents. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(97)00665-0

文献信息

• SELECTIVE CASPASE INHIBITORS AND USES THEREOF
  申请人：Ahlfors Jan-Eric

  公开号：US20120157394A1

  公开（公告）日：2012-06-21

  The present invention relates to compounds of Formula I, II, IVC, VIIIC, IXC, or XC and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, II, IVC, VIIIC, IXC, or XC are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases). Processes for synthesizing tripeptides are provided.

  本发明涉及公式I、II、IVC、VIIIC、IXC或XC化合物及其药物用途。本发明的特定方面涉及使用这些化合物选择性地抑制一个或多个半胱氨酸蛋白酶的用途。还描述了使用公式I、II、IVC、VIIIC、IXC或XC化合物在受试者中预防和/或治疗各种疾病和病状的方法，包括半胱氨酸蛋白酶介导的疾病，如败血症、心肌梗塞、缺血性卒中、脊髓损伤（SCI）、创伤性脑损伤（TBI）和神经退行性疾病（例如多发性硬化症（MS）和阿尔茨海默病、帕金森病和亨廷顿病）。还提供了三肽合成的方法。
• Selective Caspase Inhibitors and Uses Thereof
  申请人：Ahlfors Jan-Eric

  公开号：US20110077190A1

  公开（公告）日：2011-03-31

  The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

  本发明涉及公式I，IA，II，HA，III或IHA的化合物及其药物用途。本发明的特定方面涉及使用这些化合物选择性地抑制一个或多个半胱氨酸蛋白酶的用途。还描述了使用公式I，IA，II，IIA，III或IIIA的化合物防治受试者的各种疾病和病况的方法，包括半胱氨酸蛋白酶介导的疾病，如败血症、心肌梗死、缺血性中风、脊髓损伤（SCI）、创伤性脑损伤（TBI）和神经退行性疾病（例如多发性硬化症（MS）和阿尔茨海默病、帕金森病和亨廷顿病）。
• Photocatalytic Radical Coupling of Organoborates with α-Halogenated Electron-Poor Olefins
  作者：Marina Caldarelli、Sarah Jane Rezzi、Nicoletta Colombo、Tracey Pirali、Gianluca Papeo

  DOI：10.1021/acs.joc.3c02386

  日期：2024.1.5

  Herein, we report the visible-light-mediated addition of organoborates to α-halogenated electron-poor olefins enabled by an environmentally benign metal-free catalyst. The method accommodates a variety of boronic acid derivatives as well as alkenes and delivers the corresponding saturated α-halo-derivatives in up to 90% yields. The obtained products are high-value building blocks in organic synthesis

  在此，我们报告了通过环境友好的无金属催化剂实现的可见光介导的有机硼酸盐与α-卤代贫电子烯烃的加成。该方法适用于各种硼酸衍生物以及烯烃，并以高达 90% 的产率提供相应的饱和 α-卤代衍生物。所得产品是有机合成中的高价值构建模块，可进行各种后续转化。
• Selective caspase inhibitors and uses thereof
  申请人：Genesis Technologies Limited

  公开号：US10167313B2

  公开（公告）日：2019-01-01

  The present invention relates to compounds of Formula I, IA, II, IIA, III, or IIIA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

  本发明涉及式 I、IA、II、IIA、III 或 IIIA 的化合物及其药物用途。本发明的特定方面涉及这些化合物用于选择性抑制一种或多种 Caspase 的用途。还描述了将式 I、IA、II、IIA、III 或 IIIA 的化合物用于预防和/或治疗受试者的各种疾病和病症的方法，包括由 caspase 介导的疾病，如败血症、心肌梗塞、缺血性中风、脊髓损伤 (SCI)、创伤性脑损伤 (TBI) 和神经退行性疾病（如多发性硬化症 (MS) 和阿尔茨海默氏症、帕金森氏症和亨廷顿氏病）。
• WOJCIECHOWSKI, KRZYSZTOF, ORG. PREP. AND PROCED. INT., 20,(1988) N 5, C. 493-496
  作者：WOJCIECHOWSKI, KRZYSZTOF

  DOI：——

  日期：——